Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Leerink Partners from $370.00 to $351.00. They now have a "market perform" rating on the stock.
Lululemon Set to Exit Nasdaq 100 as Index Adds New Members [Yahoo! Finance]
Alnylam, Seagate among six stocks added to Nasdaq-100 in annual rebalance [Seeking Alpha]
200% Surge? These 6 Stocks Just Crashed the Nasdaq 100 Party [Yahoo! Finance]
Alnylam Pharmaceuticals: Challenges In The TTR Space And Few Late-Stage Catalysts Are A Concern [Seeking Alpha]